Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 May 10;11(1):9884.
doi: 10.1038/s41598-021-89303-3.

Factors contributing to discrepant estimated glomerular filtration values measured by creatinine and cystatin C in patients with rheumatoid arthritis

Affiliations
Observational Study

Factors contributing to discrepant estimated glomerular filtration values measured by creatinine and cystatin C in patients with rheumatoid arthritis

Akikatsu Nakashima et al. Sci Rep. .

Abstract

This study aimed to clarify the factors underlying the discrepancy that has been noted between estimated glomerular filtration ratio (eGFR) measured using serum creatinine (Cr) and eGFR using serum cystatin C (CysC) in patients with rheumatoid arthritis (RA) and to identify those patients whose renal function should be evaluated using CysC. We retrospectively evaluated clinical features, disease activity, Steinbrocker radiological staging, and co-morbidities (diabetes mellitus, hypertension, dyslipidemia) in 238 RA patients. eGFR using serum creatinine (eGFR-Cr) and eGFR using serum cystatin C (eGFR-CysC) were calculated using the new Japanese coefficient-modified Modification of Diet in Renal Disease study equation. To clarify the cause(s) of differences of 20% or more between the two eGFRs, we divided our RA patients into Group A (eGFR-Cr/eGFR-CysC ≥ 1.2) and Group B (eGFR-Cr/eGFR-CysC < 1.2), and searched for factors independently related to Group A. Forty-five patients (18.9%) were assigned to Group A, and 193 (81.1%) to Group B. BMI (Odds Ratio [OR] 0.820, 95% confidence interval [CI] 0.675-0.996), Hb (OR 0.633, 95% CI 0.433-0.926), CK (OR 0.773 per 10 units, 95% CI 0.644-0.933), NSAID use (OR 0.099, 95% CI 0.020-0.494), diabetes mellitus (OR 6.024, 95% CI 1.508-24.390) and stage 4 Steinbrocker radiological stage (OR 10.309, 95% CI 2.994-35.714) were identified as independent relevant factors for Group A by a multifactorial analysis. Renal function in RA patients with low BMI, diabetes, anemia and low CK may be overestimated using eGFR-Cr alone, and such patients need to be evaluated using eGFR-CysC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Relationship between eGFR-Cr and eGFR-CysC. eGFR-Cr; estimated glomerular filtration rate using creatinine. eGFR-CysC; estimated glomerular filtration rate using cystatin C. The correlation between eGFR-Cr and eGFR-CysC was significant (r = 0.715, p < 0.0001). However, 25 (13.8%) of 181 patients with eGFR-Cr ≥ 60 mL/min/1.73 m2 showed eGFR-Cys < 60 mL/min/1.73 m2.
Figure 2
Figure 2
Distribution of eGFR-Cr/eGFR-CysC using the histogram with a logarithmic scale on the X axis. eGFR-Cr; estimated glomerular filtration rate using creatinine. eGFR-CysC; estimated glomerular filtration rate using cystatin C. There was an inflection point at 1.2. Thus, we divided the patients into two groups by this point (greater than 20% discrepancy).

Similar articles

References

    1. Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current therapeutic options in the treatment of rheumatoid arthritis. J. Clin. Med. 2019;8:938. doi: 10.3390/jcm8070938. - DOI - PMC - PubMed
    1. Boey O, Van Hooland S, Woestenburg A, Van der Niepen P, Verbeelen D. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin. Belg. 2006;61:166–169. doi: 10.1179/acb.2006.028. - DOI - PubMed
    1. Zhang X, et al. Dose/exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis. CPT Pharmacomet. Syst. Pharmacol. 2017;6:804–813. doi: 10.1002/psp4.12251. - DOI - PMC - PubMed
    1. Karie S, et al. Kidney disease in RA patients: Prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008;47:350–354. doi: 10.1093/rheumatology/kem370. - DOI - PubMed
    1. Daoussis D, et al. Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2010;69:517–521. doi: 10.1136/ard.2008.105049. - DOI - PubMed

Publication types